Dyslipidemia Fact Sheets in Korea 2020: an Analysis of Nationwide Population-based Data
2
조회
0
다운로드
29
인용
0
참고문헌
키워드
초록
Objective: The Korean Society of Lipid and Atherosclerosis (KSoLA) has published the Dyslipidemia Fact Sheets in Korea 2020 to provide an overview of magnitude and management status of dyslipidemia and their recent trends therein. Methods: The Fact Sheets were based on the analyses of Korean adults aged 20 years or older of the 2007–2018 Korea National Health and Nutrition Examination Survey (KNHANES) and the 2002–2018 National Health Insurance Big Data (NHI-BD). Results: Between 2007 and 2018, the crude prevalence of hypercholesterolemia increased from 9.0% to 20.7%. During the same period, its management rate also improved yet remained unsatisfactory. In 2018, the prevalence of dyslipidemia was 45.6% in men and 31.3% in women, which increased with older age and presence of metabolic abnormalities. Indeed, the number of people diagnosed with dyslipidemia has increased nearly 8-fold from 1.5 million in 2002 to 11.6 million in 2018; alongside, the number of people receiving pharmacological treatment for dyslipidemia has also risen. Of the 7.7 million people treated for dyslipidemia in 2018, statin accounted for the majority (91.8%) of lipid-lowering drug prescriptions, followed by ezetimibe (14.6%), fibrate (8.5%), and omega-3 acid (5.9%). The most frequently used combination therapy was statin plus ezetimibe, accounting for 72% of dual therapy prescriptions. Conclusion: Dyslipidemia continues to impose a substantial disease burden in Korea. Both healthcare practitioners and patients need to actively adopt guideline-recommended lifestyle modification and pharmacological treatment for comprehensive, timely, and sustained management.
Abstract
Objective: The Korean Society of Lipid and Atherosclerosis (KSoLA) has published the Dyslipidemia Fact Sheets in Korea 2020 to provide an overview of magnitude and management status of dyslipidemia and their recent trends therein. Methods: The Fact Sheets were based on the analyses of Korean adults aged 20 years or older of the 2007–2018 Korea National Health and Nutrition Examination Survey (KNHANES) and the 2002–2018 National Health Insurance Big Data (NHI-BD). Results: Between 2007 and 2018, the crude prevalence of hypercholesterolemia increased from 9.0% to 20.7%. During the same period, its management rate also improved yet remained unsatisfactory. In 2018, the prevalence of dyslipidemia was 45.6% in men and 31.3% in women, which increased with older age and presence of metabolic abnormalities. Indeed, the number of people diagnosed with dyslipidemia has increased nearly 8-fold from 1.5 million in 2002 to 11.6 million in 2018; alongside, the number of people receiving pharmacological treatment for dyslipidemia has also risen. Of the 7.7 million people treated for dyslipidemia in 2018, statin accounted for the majority (91.8%) of lipid-lowering drug prescriptions, followed by ezetimibe (14.6%), fibrate (8.5%), and omega-3 acid (5.9%). The most frequently used combination therapy was statin plus ezetimibe, accounting for 72% of dual therapy prescriptions. Conclusion: Dyslipidemia continues to impose a substantial disease burden in Korea. Both healthcare practitioners and patients need to actively adopt guideline-recommended lifestyle modification and pharmacological treatment for comprehensive, timely, and sustained management.
참고문헌 (21)
- GBD 2017 Risk Factor Collaborators, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392, pp.1923~1994 (2018)
- 이승원, "Thirty-Year Trends in Mortality from Cardiovascular Diseases in Korea", Korean Circulation Journal, 45(3), pp.202~209 (2015), 대한심장학회
- Lee YR, "Measuring the economic burden of disease and injury in Korea, 2015", J Korean Med Sci, 34, pp.e80~ (2019)
- Roth GA, "Estimates of global and regional premature cardiovascular mortality in 2025", Circulation, 132, pp.1270~1282 (2015)
- Arnett DK, "2019 ACC", AHA guideline on the primary prevention of cardiovascular disease : executive summary : a report of the American College of Cardiology, Circulation, pp.2019, 140[DOI]
- Gooding HC, "Challenges and opportunities for the prevention and treatment of cardiovascular disease among young adults : report from a National Heart, Lung, and Blood Institute Working Group", J Am Heart Assoc, 9, pp.e016115~ (2020)
- Kweon S, "Data resource profile : the Korea National Health and Nutrition Examination Survey(KNHANES)", Int J Epidemiol, 43, pp.69~77 (2014)
- Seong SC, "Data resource profile : the National Health Information Database of the National Health Insurance Service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
- 이은정, "2018 Guidelines for the management of dyslipidemia", The Korean Journal of Internal Medicine, 34(4), pp.723~771 (2019), 대한내과학회[DOI]
- "National Health and Nutrition Examination Survey (NHANES) public use data files" (2021)[URL]
- "National Health and Nutrition Survey in Japan" (2015)[URL]
- Huang Y, "Epidemiology of dyslipidemia in Chinese adults : meta-analysis of prevalence, awareness, treatment, and control", Popul Health Metr, 12, pp.28~ (2014)
- 이해준, "Trends in Cardiovascular Health Metrics among Korean Adults", Korean Journal of Family Medicine, 34(6), pp.403~412 (2013), 대한가정의학회
- Ho CK, "Statins and their interactions with other lipid-modifying medications : safety issues in the elderly", Ther Adv Drug Saf, 3, pp.35~46 (2012)
- Shapiro MD, ""Cholesterol-Years"for ASCVD risk prediction and treatment", J Am Coll Cardiol, 76, pp.1517~1520 (2020)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Verbiest M, "National guidelines for smoking cessation in primary care : a literature review and evidence analysis", NPJ Prim Care Respir Med, 27, pp.2~ (2017)
- Orrow G, "Effectiveness of physical activity promotion based in primary care: systematic review and meta-analysis of randomised controlled trials", BMJ, 344, pp.e1389~ (2012)
- Sacks FM, "Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension(DASH)diet", N Engl J Med, 344, pp.3~10 (2001)
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Lalonde L, "Development of an interprofessional program for cardiovascular prevention in primary care : a participatory research approach", SAGE Open Med, 2, pp.2050312114522788~ (2014)